Study #2024-0397
A phase 1/2 study of KSQ-004EX, autologous tumor infiltrating lymphocytes engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2
Description
Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors. The safety and effects of KSQ-004EX will also be studied in both phases.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Select Advanced Solid Tumors
Study phase:
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.